Effectiveness of 23-valent pneumococcal polysaccharide vaccine against invasive disease and hospital-treated pneumonia among people aged ≤65 years: A retrospective case-control study

Clinical Infectious Diseases

Volumn 60, Issue 10, 2015, Pages 1472-1480

  Leventer Roberts, Maya ^a,b   Feldman, Becca S ^a   Brufman, Ilan ^a   Cohen Stavi, Chandra J ^a   Hoshen, Moshe ^a   Balicer, Ran D ^a,c  

^a CLALIT HEALTH SERVICES   (Israel)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

Author keywords

invasive pneumococcal disease; pneumococcal vaccination; pneumonia; vaccine effectiveness

Indexed keywords

PNEUMOCOCCUS VACCINE; POLYSACCHARIDE VACCINE; 23-VALENT PNEUMOCOCCAL CAPSULAR POLYSACCHARIDE VACCINE;

ADULT; AGE; AGED; ARTICLE; COMMUNITY ACQUIRED PNEUMONIA; CONTROLLED STUDY; FEMALE; HIGH RISK POPULATION; HUMAN; LOW RISK POPULATION; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PNEUMOCOCCAL INFECTION; PNEUMONIA; POPULATION BASED CASE CONTROL STUDY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SENSITIVITY ANALYSIS; VACCINATION; CASE CONTROL STUDY; IMMUNOLOGY; MENINGITIS, PNEUMOCOCCAL; PNEUMONIA, PNEUMOCOCCAL; STREPTOCOCCUS PNEUMONIAE; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; FEMALE; HUMANS; MALE; MENINGITIS, PNEUMOCOCCAL; PNEUMOCOCCAL VACCINES; PNEUMONIA, PNEUMOCOCCAL; RETROSPECTIVE STUDIES; STREPTOCOCCUS PNEUMONIAE; TREATMENT OUTCOME;

EID: 84929172290     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/civ096     Document Type: Article

References (39)

1. Fedson DS, Scott JA. The burden of pneumococcal disease among adults in developed and developing countries: what is and is not known. Vaccine 1999; 17(Suppl 1):S11-8.
2. Musher DM. Streptococcus pneumoniae. In: Mandell D, ed. Bennett's principles and practice of infectious diseases. 6th ed. Vol. 2. Philadelphia: Elsevier, Churchill, Livingstone, 2005:2392-410.
3. Amodio E, Costantino C, Boccalini S, Tramuto F, Maida CM, Vitale F. Estimating the burden of hospitalization for pneumococcal pneumonia in a general population aged 50 years or older and implications for vaccination strategies. Hum Vaccin Immunother 2014; 10:1337-42.
4. Vila-Corcoles A, Ochoa-Gondar O, Hospital I, et al. Protective effects of the 23-valent pneumococcal polysaccharide vaccine in the elderly population: the EVAN-65 study. Clin Infect Dis 2006; 43:860-8.
5. Blasi F, Mantero M, Santus P, Tarsia P. Understanding the burden of pneumococcal disease in adults. Clin Microbiol Infect 2012; 18(Suppl 5): S7-14.
6. Fry AM, Shay DK, Holman RC, Curns AT, Anderson LJ. Trends in hospitalizations for pneumonia among persons aged 65 years or older in the United States, 1988-2002. JAMA 2005; 294:2712-9.
7. Robinson KA, Baughman W, Rothrock G, et al. Epidemiology of invasive Streptococcus pneumoniae infections in the United States, 1995-1998: opportunities for prevention in the conjugate vaccine era. JAMA 2001; 285:1729-35.
8. Wagner C, PoppW, Posch M, Vlasich C, Rosenberger-Spitzy A. Impact of pneumococcal vaccination on morbidity and mortality of geriatric patients: a case-controlled study. Gerontology 2003; 49:246-50.
9. Nuorti JP, Whitney CG; Centers for Disease Control and Prevention . Prevention of pneumococcal disease among infants and children-use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine-recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2010; 59(RR-11):1-18.
10. Frenck RW Jr., Yeh S. The development of 13-valent pneumococcal conjugate vaccine and its possible use in adults. Expert Opin Biol Ther 2012; 12:63-77.
11. Scott DA, Komjathy SF, Hu BT, et al. Phase 1 trial of a 13-valent pneumococcal conjugate vaccine in healthy adults. Vaccine 2007; 25:6164-6.
12. Weinberger DM, Shapiro ED. Pneumococcal conjugate vaccines for adults: reasons for optimism and for caution. Hum Vaccin Immunother 2014; 10:1334-6.
13. Centers for Disease Control and Prevention. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the advisory committee on immunization practices (ACIP). MMWR Morb Mortal Wkly Rep 2012; 61:816-9.
14. Shapiro ED, Clemens JD. A controlled evaluation of the protective efficacy of pneumococcal vaccine for patients at high risk of serious pneumococcal infections. Ann Intern Med 1984; 101:325-30.
15. Shapiro ED, Berg AT, Austrian R, et al. The protective efficacy of polyvalent pneumococcal polysaccharide vaccine. N Engl J Med 1991; 325:1453-60.
16. Fine MJ, Smith MA, Carson CA, et al. Efficacy of pneumococcal vaccination in adults. A meta-Analysis of randomized controlled trials. Arch Intern Med 1994; 154:2666-77.
17. Hutchison BG, Oxman AD, Shannon HS, Lloyd S, Altmayer CA, Thomas K. Clinical effectiveness of pneumococcal vaccine. Meta-Analysis. Can Fam Physician 1999; 45:2381-93.
18. Melegaro A, Edmunds WJ. The 23-valent pneumococcal polysaccharide vaccine. Part I. Efficacy of PPV in the elderly: a comparison of metaanalyses. Eur J Epidemiol 2004; 19:353-63.
19. Cornu C, Yzebe D, Leophonte P, Gaillat J, Boissel JP, Cucherat M. Efficacy of pneumococcal polysaccharide vaccine in immunocompetent adults: a meta-Analysis of randomized trials. Vaccine 2001; 19:4780-90.
20. Moore RA,Wiffen PJ, Lipsky BA. Are the pneumococcal polysaccharide vaccines effective? Meta-Analysis of the prospective trials. BMC Family Pract 2000; 1:1.
21. Moberley S, Holden J, Tatham DP, Andrews RM. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Reviews 2013; 1:CD000422.
22. Cadeddu C, De Waure C, Gualano MR, Di Nardo F, Ricciardi W. 23-valent pneumococcal polysaccharide vaccine (PPV23) for the prevention of invasive pneumococcal diseases (IPDs) in the elderly: is it really effective? J Prev Med Hyg 2012; 53:101-3.
23. Watson L,Wilson BJ,Waugh N. Pneumococcal polysaccharide vaccine: a systematic review of clinical effectiveness in adults. Vaccine 2002; 20:2166-73.
24. Huss A, Scott P, Stuck AE, Trotter C, Egger M. Efficacy of pneumococcal vaccination in adults: a meta-Analysis. CMAJ 2009; 180:48-58.
25. Fedson DS, Liss C. Precise answers to the wrong question: prospective clinical trials and the meta-Analyses of pneumococcal vaccine in elderly and high-risk adults. Vaccine 2004; 22:927-46.
26. Wiemken TL, Carrico RM, Klein SL, et al. The effectiveness of the polysaccharide pneumococcal vaccine for the prevention of hospitalizations due to Streptococcus pneumoniae community-Acquired pneumonia in the elderly differs between the sexes: results from the Community-Acquired Pneumonia Organization (CAPO) international cohort study. Vaccine 2014; 32:2198-203.
27. Jackson LA, Neuzil KM, Yu O, et al. Effectiveness of pneumococcal polysaccharide vaccine in older adults. N Engl J Med 2003; 348: 1747-55.
28. Kawakami K, Ohkusa Y, Kuroki R, et al. Effectiveness of pneumococcal polysaccharide vaccine against pneumonia and cost analysis for the elderly who receive seasonal influenza vaccine in Japan. Vaccine 2010; 28: 7063-9.
29. Ochoa-Gondar O, Vila-Corcoles A, Rodriguez-Blanco T, et al. Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against community-Acquired pneumonia in the general population aged /=60 years: 3 years of follow-up in the CAPAMIS study. Clin Infect Dis 2014; 58:909-17.
30. Tomczyk S, Bennett NM, Stoecker C, et al. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged /=65 years: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2014; 63:822-5.
31. Cohen AD, Dreiher J, Goldfracht M, et al. The effect of the introduction of pneumococcal vaccination for adults as a quality measure on vaccination rates in Clalit Health Services [in Hebrew]. Harefuah 2011; 150:578-82, 617.
32. The Johns Hopkins Adjusted Clinical Groups System. Technical reference guide: version 9.0. Baltimore, MD: Johns Hopkins University Bloomberg School of Public Health, 2009.
33. Welte T, Torres A, Nathwani D. Clinical and economic burden of community-Acquired pneumonia among adults in Europe. Thorax 2012; 67:71-9.
34. Vila-Corcoles A, Ochoa-Gondar O, Rodriguez-Blanco T, Raga-Luria X, Gomez-Bertomeu F. Epidemiology of community-Acquired pneumonia in older adults: a population-based study. Respir Med 2009; 103:309-16.
35. Dominguez A, Salleras L, Fedson DS, et al. Effectiveness of pneumococcal vaccination for elderly people in Catalonia, Spain: a case-control study. Clin Infect Dis 2005; 40:1250-7.
36. Miyasaka T, Aoyagi T, Uchiyama B, et al. A possible relationship of natural killer T cells with humoral immune response to 23-valent pneumococcal polysaccharide vaccine in clinical settings. Vaccine 2012; 30:3304-10.
37. Kayhty H, Auranen K, Nohynek H, Dagan R, Makela H. Nasopharyngeal colonization: a target for pneumococcal vaccination. Expert Rev Vaccines 2006; 5:651-67.
38. Vila-Corcoles A, Ochoa-Gondar O, Guzman JA, Rodriguez-Blanco T, Salsench E, Fuentes CM. Effectiveness of the 23-valent polysaccharide pneumococcal vaccine against invasive pneumococcal disease in people 60 years or older. BMC Infect Dis 2010; 10:73.
39. Artz AS, Ershler WB, Longo DL. Pneumococcal vaccination and revaccination of older adults. Clin Microbiol Rev 2003; 16:308-18.